PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2010; 12(3): 121.
Published online Jun 3, 2010. doi:  10.1186/ar3004
PMCID: PMC2911861
Informed consent: time for more transparency
Yusuf Yazicicorresponding author1 and Hasan Yazici2
1New York University School of Medicine, NYU Hospital for Joint Diseases, 246 East 20th Street, New York, NY 10003, USA
2University of Istanbul, Cerrahpasa School of Medicine, Fatih, Istanbul, 34098, Turkey
corresponding authorCorresponding author.
Yusuf Yazici: yusuf.yazici/at/nyumc.org; Hasan Yazici: hasan/at/yazici.net
Abstract
Informed consent is not only for documenting a patient's acceptance of enrolling in a clinical trial. It currently is the patient's and, we propose, should also be the public's main source of information regarding the reasons for the planned study, what is known in the field about the proposed trial, and what to expect as far as efficacy and harm. Informed consent is not currently part of the clinical trial registries. For purposes of full disclosure to the patients and the public, the informed consent should be part of the required documents for such registries.
Articles from Arthritis Research & Therapy are provided here courtesy of
BioMed Central